FINWIRES · TerminalLIVE
FINWIRES

スター・スポーツ・メディシン社、最大8億3000万香港ドルの香港IPOを実施

-- スター・スポーツ・メディシン(香港証券取引所:1609)は、香港証券取引所への新規株式公開(IPO)を金曜日に開始し、約8億2,960万香港ドルの資金調達を目指している。 香港証券取引所への提出書類によると、中国に拠点を置くこの医療機器メーカーは、840万株のH株を1株あたり98.50香港ドルの価格で売り出す。 今回のIPOは、香港投資家向けに84万2,200株、海外投資家向けに760万株で構成され、再配分の対象となる。 香港でのIPOは4月29日に締め切られ、配分結果は5月4日までに発表される予定で、5月5日に上場を予定している。 調達資金は主に、生産能力の拡大と製造効率の向上、および研究開発の支援に充当される。 また、販売・マーケティング能力の強化、グローバル流通網の拡大、運転資金、および一般企業目的にも使用される。 CITIC証券(香港)とCCBインターナショナル・キャピタルが共同主幹事を務める。 CLSAとCCBインターナショナル・キャピタルは、チャイナ・ギャラクシー・インターナショナル・セキュリティーズおよびCMBCセキュリティーズと共に、全体コーディネーターを務め、共同ブックランナーも兼任します。 Futu Securities International (Hong Kong)、Open Securities、Orient Securities (Hong Kong)、およびZheshang International Financialは、共同ブックランナーおよび共同リードマネージャーを務めます。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703